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Abstract
Background: A range of evidence informs healthcare decision-making, from formal research findings to ‘soft
intelligence’ or local data, as well as practical experience or tacit knowledge. However, cultural and organisational
factors often prevent the translation of such evidence into practice. Using a multi-level framework, this project will
analyse how interactions between the evidence available and processes at the micro (individual/group) and meso
(organisational/system) levels influence decisions to introduce or diffuse innovations in acute and primary care
within the National Health Service in the UK.
Methods/design: This study will use a mixed methods design, combining qualitative and quantitative methods,
and involves four interdependent work streams: (1) rapid evidence synthesis of relevant literature with stakeholder
feedback; (2) in-depth case studies of ‘real-world’ decision-making in acute and primary care; (3) a national survey
and discrete choice experiment; and (4) development of guidance for decision-makers and evaluators to support
the use of evidence in decision-making.
Discussion: This study will enhance the understanding of decision-makers’ use of diverse forms of evidence. The
findings will provide insights into how and why some evidence does inform decisions to introduce healthcare
innovations, and why barriers persist in other cases. It will also quantify decision-makers’ preferences, including
the ‘tipping point’ of evidence needed to shift stakeholders’ views. Practical guidance will be shared with
healthcare decision-makers and evaluators on uses of evidence to enable the introduction and diffusion of
innovation.
Keywords: Cancer, Decision-making, Discrete choice experiment, Ethnography, Evidence, Innovation,
Ophthalmology, Qualitative, Service improvement, Stroke
Background
A range of evidence informs healthcare decision-making,
from formal research findings [1] to ‘soft intelligence’ or
local data [2], as well as practical experience or tacit
knowledge [3]. However, cultural and organisational fac-
tors often prevent the translation of such evidence into
practice [4]. As well as the perceived quality of the evi-
dence (e.g. due to its source) and ‘strength’ (as a working
definition, the effect or impact shown on health, costs,
and patient satisfaction), decisions to implement innova-
tions or improvements in health services are influenced
by contextual processes at the micro (individual/group),
meso (organisational/system), and macro (regulatory/
policy) levels [5]. Using a multi-level framework, this
study will analyse how interactions between the available
evidence and processes at the micro and meso levels in-
fluence decisions to introduce or diffuse innovations.
We adopt a process-based approach [6] to the study of
evidence use, defining ‘use’ as the ways in which different
stakeholders and organisations interact with evidence over
time during decision-making processes.
A preliminary, scoping review of the health services
research literature on evidence use in decision-making
concerning innovation suggests a need for new research
in three areas. First, at the micro (individual/group) level,
there is a need to determine the combinations of evidence,
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including practical or local evidence [7], used by a range
of stakeholders in decision-making, including different
professions [8] and functions or roles [9]. At the individual
level, some studies suggest that research evidence plays a
lesser role in decision-making relative to other informa-
tion [10], such as data on local needs [7]. At the group
level, access to and preferences for evidence vary by pro-
fessional group, e.g. hospital staff ’s professional back-
ground [8], while service payers (commissioners) appear
to value practical evidence [9]. How evidence is presented
also influences its use [11]. Furthermore, evidence is itself
constructed through professional practice, in which differ-
ent interests, framing of the problem, and personal experi-
ence and anecdote all play a role in establishing its
relevance and credibility [12]. Thus, further research is
needed at the micro level to determine how different stake-
holder groups, in different contexts, use evidence to inform
decision-making on innovation, including their responses
to different forms of evidence, and how potential tensions
between codified research outputs, practical evidence (e.g.
local audit data), and personal experience or tacit know-
ledge [13], are reconciled as different forms of evidence are
combined in decision-making.
Second, at the meso (organisational/system) level, there
is a need to examine how evidence informs ‘real-world’
decision-making processes through in-depth case studies
[8], taking into account organisational processes for shar-
ing knowledge [14] and other contextual factors, including
strategic fit with local priorities, financial sustainability,
and public opinion [11]. Organisational processes influ-
ence how evidence is acquired, shared, and applied to in-
form decision-making. For instance, implementation of
national clinical guidance by National Health Service
(NHS) Trusts was found to involve senior engagement,
clear organisational processes, and use of committees and
hierarchies, resources, and information systems [14].
Equally, weak processes for transferring knowledge may
act as barriers to its use in decision-making [11]; however,
a variety of ‘agencies’ at the meso and macro levels may
support the transfer or mobilisation of knowledge [15].
Thus, further research is needed at the meso level to
understand how organisational processes, including the
local system or context in which decisions are being made,
influence the use and interpretation of evidence, including
health professionals’ responses.
The inclusion of both micro and meso level processes
reflects the theorised interaction between levels in quality
improvement processes [5], i.e. organisational and other
contextual processes may shape professional responses to
evidence, while health professionals’ responses may influ-
ence the adoption of innovation in particular contexts.
Third, studies have shown that stakeholders prefer dif-
ferent types of evidence (including quality and strength)
[8, 9], but little is known about the strength of these
preferences, the potential trade-offs between these at-
tributes in relation to different types of innovation, and
how preferences vary by type of decision-maker. In
addition, little is known about how other characteristics
of evidence and other contextual factors inform decisions
to introduce or diffuse innovations. Further research is
needed to evaluate these preferences, which we will inves-
tigate using a discrete choice experiment.
Research question and objectives
To address the gaps identified in the current literature,
this study will answer the following research question:
what is the role of evidence in decision-making on the
introduction and diffusion of service innovations in
acute and primary care? In order to address this research
question, the following objectives for the study have
been defined:
1. To identify, using a literature review and stakeholder
feedback, the factors that influence the use of evidence
in decision-making on the introduction and diffusion of
innovations in health care;
2. To assess the use of evidence in informing decision-
making on the introduction and diffusion of
innovation using ‘real-world’ case studies in acute
and primary care;
3. To establish decision-makers’ preferences for evidence
(types of evidence, quality of evidence, strength of
evidence) to inform the introduction and diffusion
of innovations;
4. To develop guidance for decision-makers and
evaluators to support the evaluation and application
of evidence to enable innovation.
Methods/design
This multidisciplinary study uniquely brings together
different methodological and disciplinary perspectives
(ethnography, organisation studies, improvement science,
health economics) to study the role of evidence in
decision-making with the aim of meeting these objectives.
The following work streams, which are interdependent
and will inform one another, are planned in relation to
each objective. Methods for data collection and analysis
are described by work stream.
Work stream 1: rapid literature review and stakeholder
feedback on evidence use
The rapid review, with stakeholder feedback, has two
purposes: (a) to map the types of information used to in-
form decision-making in different contexts and (b) to
identify factors at the micro and meso levels that influ-
ence how this information informs decision-making on
innovation. We will then obtain stakeholder feedback on
the compiled evidence in relation to these purposes
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using focus groups to identify any gaps or themes that
need to be developed further.
The literature review will identify examples of evidence
use in decisions to adopt innovation from studies con-
ducted on the NHS and health systems internationally. To
identify papers, relevant social science and biomedical da-
tabases will be searched, including PubMed, ISI Web of
Knowledge, and Business Source Complete, using search
terms in the title or abstract. Search terms, that may be
combined, will include the following: ‘decision-making’,
‘service innovation’, ‘evidence use’, ‘innovation adoption or
diffusion’, ‘professional roles’, and ‘organisational factors or
processes’. A hand search of selected management and
health policy journals and books will be undertaken; bibli-
ographies of recent and highly relevant papers will also be
consulted. Studies of decision-making at the national
health system level and in public health will be excluded.
The review will be based predominantly on primary quali-
tative studies and systematic and other types of review. To
map types of information used in decision-making, we will
include quantitative studies that provide descriptive statis-
tics on evidence use, as appropriate.
Through thematic analysis of the compiled literature
[16], we will develop a conceptual framework that iden-
tifies the (a) types of evidence used to inform decision-
making in different contexts and (b) professional (micro)
and organisational (meso) processes that shape how evi-
dence is used to inform innovation adoption. The frame-
work will include decision-making in different settings
(acute and primary care) and describe these processes
from different stakeholder perspectives (service providers,
commissioners, and patient representatives). To test
and develop the thematic analysis further, we will then
obtain stakeholder feedback on the conceptual frame-
work using focus groups to identify any gaps or themes
that require further exploration. The focus groups will
also be used to determine how stakeholders define ‘ac-
ceptability’, ‘credibility’, and ‘strength’ in relation to dif-
ferent types of evidence and in relation to different
decision-making contexts.
The views of four groups of stakeholders will be obtained
through the focus groups: (1) acute care providers, (2)
primary care providers, (3) service commissioners, and
(4) patient representatives. Four focus groups, with 8–10
participants in each group, will be structured using dis-
cussion points derived from the rapid literature review.
Telephone interviews will be used for participants not
able to attend a face-to-face focus group. National par-
ticipants will be identified using different channels.
Through the National Institute of Health Research Col-
laborations for Leadership in Applied Health Research
and Care (CLAHRC) North Thames, which has 54 partners
including hospitals, local authorities, and commissioners,
we have links across the 13 CLAHRCs nationally which will
be used to reach participants.
Work stream 2: in-depth case studies
In-depth case studies will be conducted on the use of
evidence in ‘real world’ decision-making concerning the
introduction or diffusion of three service innovations in
acute and primary care. Case studies were chosen because
they allow complex phenomena to be studied in-depth,
allowing both the case (here, the use of evidence in deci-
sions to adopt innovations) and the context (professional
and organisational processes) to be taken into account, as
well as interactions between the two [17]. This approach
also addresses a need for ethnographic methods to enable
direct observation of ‘live’ decision-making processes [8].
Sampling framework for case studies
As shown in Table 1, the sampling framework for the
three case studies covers different settings (acute and
primary), innovation stages (new and diffusion), type and
strength of evidence (academic research, national guidance,
and local pilot data), and organisational contexts (including
different approaches to the implementation of innovation).
The case studies complement each other in showing
how the use of evidence to inform decision-making var-
ies across different care settings, among different types
of decision-maker, stages of innovation, and types of
Table 1 Sampling framework for case studies
Innovation case
study
Setting Innovation
stage
Evidence Context
1. Reconfiguring
stroke services
Acute; Greater Manchester (GM) and
other areas reviewing services
Diffusion ‘Strong’; research shows improvements
in mortality in London [18, 19]
Major system change;
involves multiple providers
and commissioners
2. New national
guidance on referral
for suspected cancer
Primary care; GP practices in two local
health economies with different mix
of actors supporting implementation
(clinical networks, third sector)
New ‘Inconclusive’; national guidance lowers
referral threshold [22], with the aim of
reducing emergency admissions and
diagnosing at earlier stage
Top-down change; responses
of GPs and actors at local
health economy level
3. New virtual clinics
within extended
network of eye
services
Acute/community outreach; clinics across
large metropolitan area and surrounding
region
Diffusion ‘Weak’; local pilot data suggesting
reduced patient journey time [26], but
lack of patient outcome data and
evidence for networked clinics
Organisational network;
from pilot to wider
implementation of
networked clinics
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evidence (including perceived strength). For each case
study, guiding questions aim to capture the influence of
processes at the micro (individual/group) and meso (or-
ganisational/system) levels on the use of evidence to in-
form decision-making on innovation (set out below).
Lessons from the case studies will be brought together,
with quantitative data from the national survey and discrete
choice experiment, to show how interactions between
evidence use and factors at the micro and meso levels
create a ‘tipping point’ for innovation in different contexts.
Suggestions will also be made for improving evidence use
to support innovation in less receptive settings.
Case study 1: responses to evidence on reconfiguring stroke
services
Evidence produced by members of the research team
has shown that centralising stroke services to create a
smaller number of high-volume units in London has im-
proved patient outcomes [18, 19]. This evidence has in
part influenced a decision to further centralise stroke
services in Greater Manchester [20]. A number of areas
across the UK have also reviewed the configuration of
stroke services locally and appear to be responding dif-
ferently to the evidence. For example, Greater Glasgow
and Clyde initially decided not to implement the London
model, although a further service review is planned,
while in Birmingham and the surrounding area, partial
reconfiguration of services has been undertaken, despite
support for fuller centralisation [21]. Analysing the dif-
fering responses of a number of these areas will allow
greater understanding of what is needed for evidence to
become a tipping point for change. This case study will
focus on the following:
1. At the micro level: how both stroke clinicians and
senior managers within individual provider
organisations’ use, and negotiate understandings of,
research evidence relative to other information, e.g.
financial impact and local need, when considering
reconfiguration.
2. At the meso level: how individual ‘champions’ and
collective decision-making groups influence how
evidence is used and consensus reached among
providers and commissioners across health systems
considering reconfiguration.
Case study 2: uptake of new national guidance in primary
care to improve early diagnosis of suspected cancer
In 2015, NICE updated its clinical guidelines [22] for
recognition and referral for suspected cancer which sub-
stantially lowered thresholds for investigation and shifted
focus to signs and symptoms, to reflect how patients
present in primary care. The guidance seeks to improve
the quality and timeliness of diagnosis and, if implemented,
is likely to significantly increase referrals. NICE has
produced costing tools to help areas respond to poten-
tial demand increases and associated cost impacts
[23]. Uptake may be influenced by general practitioners’
(GPs) responses to the guidelines [24] and the local
context including, on the one hand, local activity by a
wide range of organisations encouraging implementa-
tion while, on the other, potential pressure from hospi-
tals and commissioners not to over-refer [25]. However,
NICE also recommends that some investigations are now
arranged in primary care (e.g. for colorectal cancer) when
these previously required referral. This case will examine
the following:
1. At the micro level: how general practitioners within
primary care practices with historically lower and
higher referral rates for suspected cancer have
responded to new guidance, including profession-
specific barriers and facilitators.
2. At the meso level: how involvement and interaction
between different organisations, including clinical
networks, commissioners, third sector, and service
providers, have influenced responses to the referral
guidance and its use to inform service planning.
Case study 3: using evidence to inform development of new
virtual clinics within extended network of eye services
We will study innovations in outpatient services for
treating chronic eye disease where demographic change
is placing increasing pressure on hospitals. New service
configurations are being developed by a number of pro-
viders within the NHS. The study will be conducted with a
large specialist provider of ophthalmic services in England,
which delivers 470,000 outpatient appointments per year
through an organisational network (including partnerships
with other providers) with multiple clinics across a large
metropolitan area and the surrounding region. The Trust
has piloted ‘virtual review’ clinics for stable glaucoma pa-
tients to improve resource use and enable provision closer
to patients’ homes, although barriers to implementation
were encountered [26].
A prospective study will analyse how evidence informs
decision-making by the Trust and other providers within
the network to move from the pilot phase to a wider
implementation of virtual clinics across other sites, in-
cluding responses to evidence for change by different
sites and professional groups. This case will focus on
the following:
1. At the micro level: types of evidence required by
different professional groups, including clinical and
managerial staff, to support roll-out of new clinics.
2. At the meso level: processes across the
organisational network used to acquire, share, and
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interpret evidence to inform decision-making. This
will include analysis of how counter evidence and
other factors, e.g. perceived resource implications
and local need, are negotiated and inform decision-
making.
Case study data will be collected through semi-structured
interviews, non-participant observation, and documentary
analysis (Table 2). Interviews will be used to develop an
account of the decision-making process from different
stakeholder perspectives and obtain their views on bar-
riers and enablers to the use of evidence as a tipping
point for adopting innovation. Documentary analysis
will map the types of evidence used at different stages
of the decision-making process. For prospective studies
(case studies 2 and 3), ethnographic methods, including
non-participant observation of meetings and ‘shadow-
ing’ key staff, will be used to trace decision-making
processes prospectively (i.e. in ‘real time’) and examine
how evidence is considered by decision-makers in both
formal (e.g. planning meetings) and informal settings
(e.g. corridor conversations). Documentary analysis will
involve mapping the types of evidence used to inform
decision-making and the ways in which it is consulted
during different stages of decision-making processes,
e.g. tracking references in meetings’ minutes. Interviews
will be digitally recorded and professionally transcribed,
and observational data will be recorded by the researchers
in field journals.
The analysis of qualitative data from the case studies
will combine inductive and deductive approaches [27],
as thematic analysis will draw on ideas emerging from
the empirical data as well as existing literature on
evidence use in decision-making processes, including
the role of contextual factors. Cross-case comparison
will identify barriers and enablers of evidence use to
support innovation at the micro and meso levels
within the same setting and at the same level across
different cases.
Work stream 3: national survey and discrete choice
experiment (DCE) to establish decision-makers’ preferences
Utilising the literature review, stakeholder feedback, and
case study data, a survey of providers and commissioners
will assess how preferences to introduce or diffuse innova-
tions are influenced by characteristics of the evidence for
change relative to other contextual factors (objective 3).
The first part of the questionnaire will elicit preferences for
different types and quality of evidence. The second part will
be a DCE that will compare different decision-making
groups’ preferences for the strength of evidence to examine
tipping points in preferring one option over another.
We will develop a survey questionnaire for distribution
to stakeholders (acute and primary care, providers, com-
missioners, managers, and clinicians). The questionnaire
will have two parts. The first will contain questions
about preferences for different types of evidence and
quality of the evidence when judging whether or not
to implement a new innovation. Types of evidence will
include impact on health (mortality, quality of life);
behaviour; knowledge; use of services; budget; and in-
cremental cost-effectiveness. Quality of evidence will
capture internal and external validities (e.g. extent to
which evidence shows what it purports to show, extent
to which findings are generalisable to the local area)
and contextual factors (e.g. credibility of the person or
organisation providing the evidence). We will ask re-
spondents whether or not different types and quality
of evidence are important and to rank them in order
of importance. The different types and quality of evi-
dence will be drawn from findings of the rapid review,
focus groups, and case studies.
The second part will be a DCE to capture preferences
of stakeholders for the strength of evidence needed (e.g.
what the impact on health or the budget needs to be) to
implement new innovations and how types of evidence
are traded against one another.
The DCE will follow international best-practice guide-
lines [28] and be designed as follows:
Table 2 Data collection methods for case studies
Innovation case study Interviews Observations Documentary analysis
1. Reconfiguring
stroke services
Up to 25, including commissioners
and providers of services in GM
and other areas considering
reconfiguration
Up to 20 h, including planning meetings
at Trust level, commissioner and provider
meetings, and other relevant decision-
making authorities
Up to 100 documents, including
meeting minutes, published research,
grey literature, local data
2. National guidance for
referral for suspected cancer
Up to 25 across two local health
economies, including GP practices,
clinical networks, and third sector
Up to 40 h, including commissioning
meetings, GP training events, service
planning meetings
Up to 50 documents, including
guidelines, local service planning
3. New virtual clinics within
extended network of eye
services
Up to 25, including Trust board
members, those leading innovation,
and staff involved in implementation
Up to 40 h, including board meetings;
innovation planning meetings, e.g.
steering group; local planning in
satellite sites; and shadowing key staff
Up to 50 documents, including
meeting minutes, published research,
grey literature, local data
Total 75 interviews 100 h 200 documents
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1. We will identify types of evidence as described in
the first part of the questionnaire. In the context of
a DCE, these are referred to as attributes.
2. We will assign levels to these attributes (e.g.
quantitative measurement of impact on health and
use of services) based on real-world examples of
innovations, derived from objectives 1 and 2 and
systematic literature reviews.
3. We will design the DCE questionnaire using a
pairwise choice framework. We will compile a set
of pairwise scenarios that describe the feasible
combinations of levels and attributes of new
innovations. The number of pairwise choices will
be reduced to a practical number for participants
to answer.
The questionnaire will be piloted then administered to
three groups of respondents: (1) acute care providers,
(2) local commissioners, and (3) primary care providers
(GPs and practice staff ). Both managerial and clinical
representatives will be sampled in the questionnaire.
Responses will be collected by online survey tools and
hard-copy questionnaires delivered at face-to-face meet-
ings. We will sample questionnaire respondents nationally
and will use similar sampling methods to objective 1. We
will also recruit respondents via newsletters distributed by
Royal Colleges, professional organisations, and at profes-
sional conferences and meetings.
Sample size calculations for DCEs are not straightfor-
ward, depending on question format, complexity of choice
tasks, desired precision of the results, degree of heterogen-
eity in the target population, availability of respondents,
and need for subgroup analyses. A sample size of 300 is
commonly recommended [29], which will be used here.
We are not aware of any DCEs that have previously been
conducted on this sample of respondents, but response
rates achieved in previous DCEs with UK NHS staff
have been around 55 % [30], and in health workers in
high-income countries, they are around 50 % [31]. The
same respondents will also complete the first part of
the questionnaire, described above.
To analyse the data from the first part of the question-
naire, frequency tables will be created to describe whether
or not different types and quality of evidence are import-
ant. We will cross-tabulate the responses by type of re-
spondent and explore differences using chi-square tests.
We will investigate differences in the ranking of different
types and quality of evidence using rank-sum tests and
Kendall’s coefficient of concordance.
The DCE data will be analysed using conditional logit
regression analysis. The results will indicate which attri-
bute (type of evidence) is most important to respondents
and how this compares with the other attributes. We
will explore the trade-offs the participants are willing to
make between attributes, quantified using the marginal
rates of substitution, which summarise how respondents
trade-off values of the different attributes, e.g. what in-
crease in total spending decision-makers are willing to
trade-off for a 1 % reduction in mortality. We will model
interaction effects, allowing us to investigate how prefer-
ences for one attribute vary dependent on another (e.g.
impact of mortality on preferences at different levels of
budget impact). We will also determine the predicted
probability that a set of new innovations derived from
different combinations of attributes would be selected
based on the regression results. This will estimate the
probability that innovations with particular values for
the types of evidence will be selected and allows them to
be ranked in terms of their order of preference.
Work stream 4: developing guidance to improve evidence
use
Combining findings from the literature review, focus
groups, case studies, and DCE, factors to take into account
when seeking, using, and producing evidence will be dis-
tilled into guidance for decision-makers and evaluators to
inform decisions to introduce or adopt innovations. This
may build on Lavis et al.’s five questions to inform strat-
egies to improve the use of evidence by decision-makers
(message, target audience, messenger, transfer processes,
and evaluation) [32]. The guidance will describe the com-
binations of evidence (including type, strength, and pres-
entation) needed to enable innovation, based on what is
likely to satisfy different stakeholders in different contexts
(e.g. in primary and acute care and innovation across sin-
gle or multiple sites). A stakeholder workshop involving
study participants will be held to gain feedback on the
draft guidance as it is developed.
Synthesis of quantitative and qualitative approaches
Our overall approach is to use mixed or ‘merged’
methods, which involves the integration of quantitative
and qualitative methods [33]. This will be done in three
ways. Firstly, the literature review will include both
qualitative studies and descriptive statistics on evidence
use, so that the relative influence of different forms of
evidence on decision-making can be quantified, where
such data exist. Secondly, findings from the stakeholder
focus groups and case studies will inform the discrete
choice experiment, as types of evidence use identified
through the qualitative research will be included in the
questionnaire and measured quantitatively. Thirdly, the
dissemination of findings on evidence use will include
both qualitative data on how different forms of evidence
are used to inform decision-making as well as quantitative
data on the contribution of different forms of information
to decision-making in different contexts.
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Discussion
This study will enhance understanding of decision-
makers’ use of diverse forms of evidence and the import-
ance of contextual factors in shaping the ways in which
evidence is used to inform decision-making on innovation.
The findings will enhance understanding of how and why
some evidence does inform decisions to introduce health
care innovations and why barriers persist in other cases. It
will also quantify decision-makers’ preferences, including
the tipping point of evidence needed to shift stakeholders’
views. Guidance will be shared with key groups of
decision-makers at different levels of the NHS, as well as
evaluators, to inform how evidence is produced and used
to satisfy a range of stakeholders when making decisions
on adopting innovations. The study’s findings will improve
understanding of how evidence can inform practice, in-
cluding barriers and facilitators to its use. The study will
produce generalisable knowledge on how to optimize the
use of evidence to inform decisions on innovation adop-
tion which, in turn, may help to accelerate and maximise
the implementation of practices that improve patient
outcomes.
The evidence needed to reach the tipping point for
different groups will be determined using a DCE with
providers and commissioners within both acute and
primary care settings. A strength of this study is the
use of quantitative and qualitative data to determine
decision-makers’ preferences. The DCE will seek to
measure the influence of diverse evidence and contextual
factors, including professional interests and relationships,
on decision-making. Thus, a practical challenge is translat-
ing insights from the qualitative data into appropriate op-
tions that can be used for eliciting participants’ preferences.
For instance, if the qualitative data suggests that decision-
making is a distributed process that unfolds over time, this
might suggest the need to adapt the model of the lone, con-
templative decision-maker typically used in a DCE (e.g. by
administering the DCE to groups of participants rather
than individuals).
The study’s findings will provide new insights into the
ways in which evidence informs both the adoption of new
innovations and the diffusion of existing innovations to
new contexts, taking into account diverse types of evidence
(e.g. academic research and local pilot data), different types
of stakeholder, and contextual factors involved in decision-
making. By combining qualitative and quantitative
methods, the study will generate new knowledge regarding
the types and quality of evidence that decision-makers
prefer and the tipping point of evidence necessary to shift
the perspectives of different groups of decision-makers.
This includes groups or contexts that may typically be less
receptive to change, e.g. medical professionals [34, 35],
and where major system change is undertaken that in-
volves multiple organisations and stakeholders [36].
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